Blurbs

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Aytu BioScience (AYTU) and Aquestive Therapeutics (AQST)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCULResearch Report), Aytu BioScience (AYTUResearch Report) and Aquestive Therapeutics (AQSTResearch Report) with bullish sentiments.

Ocular Therapeutix (OCUL)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix, with a price target of $10.00. The company’s shares closed last Tuesday at $4.31, close to its 52-week low of $2.91.

According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.3% and a 26.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Bausch + Lomb Corporation, and EyePoint Pharmaceuticals.

Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $15.00, a 197.0% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Aytu BioScience (AYTU)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aytu BioScience, with a price target of $6.00. The company’s shares closed last Tuesday at $0.19, close to its 52-week low of $0.18.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 20.9% and a 33.5% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Finch Therapeutics Group, Eledon Pharmaceuticals, and Aridis Pharmaceuticals.

Currently, the analyst consensus on Aytu BioScience is a Moderate Buy with an average price target of $6.00.

Aquestive Therapeutics (AQST)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics, with a price target of $5.00. The company’s shares closed last Tuesday at $1.14, close to its 52-week low of $0.62.

According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -36.1% and a 13.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Fresh Tracks Therapeutics.

Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $6.50, a 417.9% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCUL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos